25 January 2017
3QFY17 Results Update | Sector: Technology
Wipro
BSE SENSEX
27,708
Bloomberg
Equity Shares (m)
M.Cap.(INRb)/(USDb)
52-Week Range (INR)
1, 6, 12 Rel. Per (%)
Avg Val, INRm
Free float (%)
S&P CNX
8,603
WPRO IN
India/ME and Healthcare headwinds cast shadow over near term
2,431
Organic revenue declines QoQ CC:
WPRO’s 3QFY17 CC revenue growth of
1,150.9 / 16.9
0.6% QoQ was marginally below our estimate of +1.3% QoQ, and in the
607 / 410
lower half of the company’s guided band of 0-2%. Five weeks of revenue
-3/-13/-27
from the Appirio integration (~1.1% contribution) meant that organic
845
26.8
revenue declined 0.5% QoQ CC. Energy & Natural Resources grew 2.1% QoQ
CMP: INR474
TP: INR540(+14%)
Neutral
Financials & Valuations (INR b)
2016 2017E
Y/E Mar
512.4
550.8
Net Sales
108.1
109.6
EBITDA
88.9
82.4
PAT
36.1
33.4
EPS (INR)
2.9
-7.4
Gr. (%)
189.7
204.5
BV/Sh (INR)
20.3
17.0
RoE (%)
16.7
13.7
RoCE (%)
13.1
14.2
P/E (x)
2.5
2.3
P/BV (x)
2018E
595.8
124.6
90.1
37.2
11.1
229.4
17.0
14.4
12.7
2.1
Estimate change
TP change
Rating change
CC, while all other verticals grew below 1%. In terms of geographies, India &
ME declined 4.2% QoQ CC, while other geographies grew between 1-2%.
Strong execution aids margin beat:
IT Services EBIT margin was 18.3%
(+50bp QoQ), above our estimate of 17.2%, led by strong execution despite
headwinds from lower working days. Overall EBIT margin was 16.4%, in line
with our estimate of 16.2%, implying continued losses in products segment.
PAT grew 2.0% QoQ to INR21b, marginally below our estimate of INR21.9b.
Headwinds to India/ME and Healthcare mar guidance:
For 4QFY17, WPRO
guided for growth of 1-2% QoQ CC. However, excluding ~7 weeks of
expected Appirio revenues (~1.5%), the guidance for organic revenue is
-0.5% to +0.5% QoQ CC, or flat at the midpoint. WPRO’s restructuring in
India/ME business is expected to complete in a few quarters, and Healthcare
is reeling from uncertainty around the future of Affordable Care Act under
the new US President. These segments together contribute 26% of WPRO’s
revenues assuming no overlap.
Valuation view:
We cut forward revenue estimates by 2.4-2.9% and
earnings estimates by 5.4-5.9%, factoring in fresh concerns around
Healthcare in addition to ongoing India restructuring. Over FY16-19, we
expect USD revenue/EPS CAGR of 5%/6%. While valuations at 12.7x FY18E
appear inexpensive, multiple re-rating will elude as long as portfolio issues
drag growth. Our TP of INR540 discounts FY19E earnings by 13x.
Neutral.
Quarterly Performance (Consolidated)
Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.
Ashish Chopra
(Ashish.Chopra@MotilalOswal.com); +91 22 6129 1530
Sagar Lele
(Sagar.Lele@MotilalOswal.com); +91 22 6129 1531